文献速递肝病

评估肝硬化患者的药物使用、障碍与知识:My Cirrhosis Coach 问卷的开发与验证

Measuring Medication Use, Obstacles, and Knowledge in Individuals With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-31

在3家三级中心前瞻性纳入713例肝硬化成人,开发并验证自填式问卷「My Cirrhosis Coach」(MCC),评估药物使用、障碍与知识。MCC六因子模型拟合良好,内容效度指数81%-94%,专家准确度评分91%-100%,各领域均分1.1-2.6(范围0-3)。作者认为MCC可用于标准化肝硬化临床实践与教育研究中的药物使用和知识测量。

要点

  • MCC为自填式问卷,含药物使用与可及性、药物障碍、乳果糖使用、利尿剂使用、β受体阻滞剂使用、膳食钠使用6个领域。
  • 有相应并发症者在该并发症相关药物领域得分更高,如腹水患者的利尿剂使用得分。
  • 住院患者除盐使用外所有知识领域得分均高于门诊患者,且报告更多药物障碍。

核心结论

  • 在大型多样化队列中验证了MCC,可用于标准化肝硬化临床实践与教育研究中的药物使用和知识测量。

研究设计与样本

  • 前瞻性队列研究,2016年7月至2020年7月在3家三级中心纳入成人肝硬化患者,共713例。
  • 采用心理测量学方法包括验证性因子分析开发和验证最终问卷,并通过内容效度指数和专家表现评估内容效度。
  • 通过比较假设表现不同的组间得分评估区分效度。

主要发现

  • 队列中腹水占45%、肝性脑病占33%,终末期肝病模型-钠中位数10(四分位距9-15)。
  • MCC六因子模型拟合良好:近似误差均方根0.22,比较拟合指数0.96,标准化残差均方根0.104。
  • 专家评定内容效度指数81%-94%,准确度评分91%-100%;各领域均分1.1-2.6(范围0-3,3表示表现更好)。
  • 有肝硬化并发症者在相应药物领域得分更高,如腹水患者的利尿剂使用得分。
  • 与门诊患者相比,住院患者除盐使用外所有知识领域得分更高,且报告更多药物障碍;得分因收入、教育水平及家中是否有成人而不同。

关键数值与推荐

  • MCC最终领域:药物使用与可及性、药物障碍、乳果糖使用、利尿剂使用、β受体阻滞剂使用、膳食钠使用。
  • 各领域得分范围0-3,3表示表现更好,均分范围为1.1-2.6。
  • 内容效度指数81%-94%,专家准确度评分91%-100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although patient knowledge is modifiable, there are no widely accepted tools to measure patient understanding during cirrhosis care. We aimed to develop and validate "My Cirrhosis Coach" (MCC), a personalized, self-administered questionnaire to evaluate cirrhosis-related medication use, obstacles, and understanding. METHODS: Adults with cirrhosis were prospectively enrolled at 3 tertiary centers from July 2016 through July 2020. Psychometrics including confirmatory factor analysis was used to develop and validate a final questionnaire. Content validity was measured via the content validity index and expert performance. Discriminant validity was assessed by comparing scores between groups hypothesized to have varying performance. RESULTS: The MCC was tested in a diverse cohort (n = 713) with cirrhosis and its complications including ascites (45%) and hepatic encephalopathy (33%) with median Model for End-Stage Liver Disease-Sodium 10 (interquartile range, 9-15). A 6-factor model of the MCC fit the data well (root mean square error of approximation, 0.22; comparative fit index, 0.96; standardized root mean squared residual, 0.104; final domains: Medication Use & Accessibility, Medication Obstacles, Lactulose Use, Diuretic Use, Beta Blocker Use, and Dietary Sodium Use). The MCC had excellent content validity (content validity index, 81%-94%) and accuracy (91%-100%) ratings by experts. Mean domain scores ranged from 1.1 to 2.6 (range, 0-3; 3 indicating better performance). Those with a cirrhosis complication scored higher in the relevant medication domain (ie, diuretic use score in ascites). Compared with outpatients, inpatients scored higher in all knowledge domains except salt use and reported more medication obstacles. Scores differed by income, education level, and having an adult at home. CONCLUSIONS: In a large, diverse cohort, we validated the MCC, which can serve to standardize medication use and knowledge measurement in clinical practice and education-based studies in cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Desai AP, Duzdar S, Stump T, et al. Measuring Medication Use, Obstacles, and Knowledge in Individuals With Cirrhosis. Clin Gastroenterol Hepatol. 2022. PMID: 36055568. doi:10.1016/j.cgh.2022.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。